Effect of a selective COX-2 inhibitor, celecoxib, on heterotopic ossification after total hip arthroplasty: A case-controlled study

Julius K. Oni, Joseph R. Pinero, Bryan M. Saltzman, Fredrick F. Jaffe

Research output: Contribution to journalArticlepeer-review

Abstract

Heterotopic ossification (HO) is a well-known complication of total hip arthroplasty (THA), especially when the direct lateral approach is used. In this study, we examined the effect of the selective COX-2 inhibitor, celecoxib, on the rates of HO after THA. A control group consisting of 108 patients that did not receive celecoxib was compared with a study group consisting of 106 patients that did receive celecoxib. We assessed the presence and grade of HO using the Brooker classification and Harris hip scores were determined pre-and postoperatively to better quantify clinical outcomes. In this retrospective study of prospectively collected data, celecoxib is associated with a significant reduction in the incidence of HO in patients undergoing THA.

Original languageEnglish (US)
Pages (from-to)256-262
Number of pages7
JournalHIP International
Volume24
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Keywords

  • Celecoxib
  • Cyclooxygenase-2
  • Heterotopic
  • Ossification
  • Postoperative complication
  • Total hip replacement

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'Effect of a selective COX-2 inhibitor, celecoxib, on heterotopic ossification after total hip arthroplasty: A case-controlled study'. Together they form a unique fingerprint.

Cite this